

## United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/487,790	7,790 01/20/2000		Raphael Gorodetsky	995/46	3576	
28765	7590	02/24/2006		EXAMINER		
WINSTON	& STRA	WN LLP	LIU, SAMUEL W			
1700 K STR				ART UNIT PAPER NUMBER		
WASHINGTON, DC 20006				1653		

DATE MAILED: 02/24/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

## Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
09/487,790	GORODETSKY ET AL.		
Examiner	Art Unit		
Samuel W. Liu	1653		

	Samuel W. Liu	1653						
The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondence add	ress					
THE REPLY FILED 03 February 2006 FAILS TO PLACE THIS	APPLICATION IN CONDITION FO	R ALLOWANCE.						
1.  The reply was filed after a final rejection, but prior to or on this application, applicant must timely file one of the follow places the application in condition for allowance; (2) a No a Request for Continued Examination (RCE) in compliance time periods:	wing replies: (1) an amendment, aff stice of Appeal (with appeal fee) in c	idavit, or other evider compliance with 37 C	nce, which FR 41.31; or (3)					
a) The period for reply expires 7 months from the mailing date								
b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.								
Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).								
Extensions of time may be obtained under 37 CFR 1.136(a). The date have been filed is the date for purposes of determining the period of ex under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b) NOTICE OF APPEAL	tension and the corresponding amount shortened statutory period for reply origi r than three months after the mailing da	of the fee. The approprinally set in the final Offi	iate extension fee ice action: or (2) as					
<ol> <li>The Notice of Appeal was filed on <u>03 February 2006</u>. A bethe date of filing the Notice of Appeal (37 CFR 41.37(a)), appeal. Since a Notice of Appeal has been filed, any replication.</li> </ol>	or any extension thereof (37 CFR 4	11.37(e)), to avoid dis	missal of the					
AMENDMENTS								
<ol> <li>The proposed amendment(s) filed after a final rejection,</li> <li>They raise new issues that would require further co</li> <li>They raise the issue of new matter (see NOTE belo</li> </ol>	nsideration and/or search (see NO w);	TE below);						
(c) They are not deemed to place the application in being appeal; and/or			the issues for					
(d) They present additional claims without canceling a NOTE: (See 37 CFR 1.116 and 41.33(a)).		ected claims.						
4. The amendments are not in compliance with 37 CFR 1.1		mpliant Amendment	(PTOL-324).					
5. Applicant's reply has overcome the following rejection(s)	: under 35 USC 112, first paragrap	h and second paragr	raph.					
<ol> <li>Newly proposed or amended claim(s) would be all non-allowable claim(s).</li> </ol>	llowable if submitted in a separate,	timely filed amendme	ent canceling the					
7.  For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is pro The status of the claim(s) is (or will be) as follows:	will not be entered, or b)      will will will will will will will	ll be entered and an e	explanation of					
Claim(s) allowed: <u>none</u> .								
Claim(s) objected to: <u>none</u> .								
Claim(s) rejected: <u>1 and 10-12</u> . Claim(s) withdrawn from consideration: <u>none</u> .								
AFFIDAVIT OR OTHER EVIDENCE								
<ol> <li>The affidavit or other evidence filed after a final action, bu because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).</li> </ol>	t before or on the date of filing a No d sufficient reasons why the affidav	otice of Appeal will <u>no</u> it or other evidence is	nt be entered s necessary and					
<ol> <li>The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to o showing a good and sufficient reasons why it is necessary</li> </ol>	vercome all rejections under appea	al and/or appellant fai	ils to provide a					
10. ☐ The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER								
<ol> <li>The request for reconsideration has been considered bu <u>See Continuation Sheet.</u></li> </ol>	t does NOT place the application ir	n condition for allowar	nce because:					
12. Note the attached Information Disclosure Statement(s).	(PTO/SB/08 or PTO-1449) Paper N	lo(s)						
13.  Other:								

Continuation of 11. does NOT place the application in condition for allowance because: The amendment filed 2/3/06 overcomes the rejections under 35USC 112, first paragraph, and second paragraph; and amendment does not obviate the rejections under 35USC 102(b) by Henschen at el. and under 35USC 102(e) by Pandya et al. because of the following reasons.

The specification does not provide definition for the phrase "synthetic peptide", which therefore broadly encompasses any peptide/polypeptide biologically synthesized, recombinantly produced thereof, and chemically synthesized thereof. Furthermore, the specification teaches that the haptotatic peptide of the current invention is encoded by DNA sequence (see page 22, lines 15-20), indicating/suggesting that the peptide can be biosynthesized in vivo. Therefore, the references (Henschen et al. and Pandya et al.) are qualified for 102 and/or 103 art over the claimed invention (see below).

Note that the claim 1 language "a synthetic peptide derived from the carboxyl terminal sequence of human fibrinogen b chain having an amino acid sequence as set forth in SEQ ID NO:1" reads on any (size of) polypeptide/peptide comprising said SEQ ID NO:1 wherein the peptide/polypeptide is not unmodified fibrinogen, in view of that the polypeptide/peptide is biosynthesized in vivo (see the above statement).

Henschen et al. teach the modified human fibrinogen protein (see abstract) comprising the SEQ ID NO:1 sequence having the haptotatic activity. Thus, the rejection under 35 USC 102(b) to claim1 stands.

Similarity, Pandya et al. teach the modified human fibrinogen polypeptide comprising b-chain which lacks the first 42 amino acid residues of the full-length b-chain, and comprise the C-terminal sequence (residues 441-462) of said polypeptide, wherein said C-terminal sequence consists of the instant SEQ ID NO:1 (KGSWYSMRKMSMKKIRPFFPQQ) having haptotatic activity. Thus, the rejection under 35 USC 102(e)/103(a) to claims 1 and 10-12 stands.

JON WEBER
SUPERVISORY PATENT EXAMINER